Skip to content
OpenCapital
Get started

Gilead Sciences GILD Sofosbuvir/Velpatasvir — Total revenues

Other product segments

Biktarvy
$3.36B+6.7%
Descovy
$807M+37.7%
Trodelvy
$402M+37.2%
Yescarta
$332M-14.0%
Genvoya
$264M-27.5%
Vemlidy
$237M-6.0%
Odefsey
$221M-21.4%
Yeztugo
$166M—
Veklury
$144M-52.3%
AmBisome
$138M-0.7%
Symtuza - Revenue share
$138M+21.1%
Livdelzi
$133M+233%
Other Liver Disease
$114M-5.8%
Tecartus
$75M-3.8%
Other HIV
$73M-19.8%
Other
$58M-17.1%
Royalty, contract and other revenues
$14M-74.1%

Similar metrics at other companies

Biogen logo
BIIBPLEGRIDY — Total Revenue
$64.3M+8.1%
Ionis Pharmaceuticals logo
IONSBepirovirsen — Revenue
$15M—
Biogen logo
BIIBRevenue from anti-CD20 therapeutic programs — Total Revenue
$419.1M+10.8%
Incyte logo
INCYNet sales — Total revenues
$1.1B+19.8%
Biogen logo
BIIBInterferon — Total Revenue
$227.5M+0.5%
Biogen logo
BIIBQALSODY — Total Revenue
$32.5M+110%

Other financials

Income statement

See full
Revenue$7.0B+4.4%
Gross profit$5.5B+7.6%
Operating income$2.6B+15.6%
Net income$2.0B+53.7%
EPS (diluted)$1.61+54.8%

Balance sheet

See full
Cash & equivalents$7.6B-3.8%
Total debt$22.2B-11.1%
Total equity$23.5B+22.7%
Total assets$56.3B-0.3%

Cash flow

See full
Operating cash flow$2.5B+44.8%
CapEx$117.0M+12.5%
Free cash flow$2.4B+46.8%

Valuation

See full
Market cap$153.66B+23.8%
Enterprise value$168.2B+19.7%
P/E16.7×-4.1×
P/S5.2×+0.8×

Profitability

See full
Gross margin79.4%+1.1pp
Operating margin34.9%+6.3pp
Net margin31%+10.2pp

Returns & leverage

See full
Return on equity43.2%+10.7pp
Debt / equity0.9×-0.4×
Current ratio2×+0.6×

Where this comes from

Reported directly by Gilead Sciences in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gilead Sciences's sofosbuvir/velpatasvir — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Gilead Sciences's sofosbuvir/velpatasvir — total revenues?
Gilead Sciences (GILD) reported sofosbuvir/velpatasvir — total revenues of $283M in Q1 2026.
How has Gilead Sciences's sofosbuvir/velpatasvir — total revenues changed year-over-year?
Gilead Sciences's sofosbuvir/velpatasvir — total revenues decreased by 18.2% year-over-year, from $346M to $283M.
What is the long-term trend for Gilead Sciences's sofosbuvir/velpatasvir — total revenues?
Over 3 years (2022 to 2025), Gilead Sciences's sofosbuvir/velpatasvir — total revenues has grown at a -5.9% compound annual growth rate (CAGR), from $1.53B to $1.27B.
What does sofosbuvir/velpatasvir — total revenues mean?
The total sales revenue generated from the company's specific hepatitis C antiviral medication.
How do you interpret sofosbuvir/velpatasvir — total revenues?
An increase indicates strong market adoption and sustained demand for the therapy, while a decrease may signal increased competition, patent expirations, or a shift in the patient population requiring treatment.
How does sofosbuvir/velpatasvir — total revenues compare across companies?
Comparable to revenue streams from specialized antiviral or chronic disease therapeutic product lines at other major pharmaceutical companies.